MCAT

MALVERN, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, today announced its financial and operating results for the third quarter of 2022. Third Quarter 2022 Highlights Third quarter 2022 revenue of $16.5 million, represents a 20% increase as compared to the third quarter 2021 Achieved record quarterly U.S. treatment session revenue of $11.9 million in the third quarter 2022, compared to $10.3 million in third quarter 2021 Reached an all time U.S. treatment session utilization record in the third quarter Increased NeuroStar System revenue 51% over the third quarter of 2021 Raising revenue guidance for full year 2022 to be between $63.0 million and $64.0 million Recent Operational Highlights Received FDA 510(k) clearance for D-Tect™ MT Accessory Positive TMS coverage policies published or proposed which expand patient access to NeuroStar Advanced Therapy system for both MDD and OCD Recent Marketing Highlights Grand opening of NeuroStar University (NSU) in Charlotte, North Carolina Tap Into a New Possibility for Depression campaign drove over 30 million impressions, up 150% compared to campaigns run during third quarter of 2021 Achieved milestones of over 141,070 global patients treated with more than 5.0 million of our Treatment Sessions, a Company record “Our strong performance in the third quarter reflects the positive impacts of our ongoing strategic initiatives such as the revamped sales force, innovative marketing programs, and continued physician and patient education. Performance was highlighted by record US Treatment Sessions revenue and utilization, while also achieving 51% year-over-year growth in US NeuroStar System revenue,” said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics. “We will continue to concentrate on execution for the remainder of the year in order to fuel growth and put ourselves in a position to achieve cash flow breakeven in 2024.” Third Quarter 2022 Financial and Operating Results for the Three Months Ended September 30, 2022 Revenues by Geography Three Months Ended September 30, 2022 2021 Amount Amount % Change (in thousands, except percentages) United States $ 16,244 $ 13,280 22 % International 254 519 (51) % Total revenues $ 16,498 $ 13,799 20 % Total revenue for the three months ended September 30, 2022 was $16.5 million, an increase of 20% compared to the three months ended September 30, 2021 revenue of $13.8 million. During the quarter, total U.S. revenue increased by 22% and international revenue decreased by 51% over the prior year quarter. The U.S. revenue growth was primarily driven by an increase in Treatment Session sales and the decline in international revenue was primarily driven by the timing of orders in early 2022. U.S. Revenues by Product Category Three Months Ended September 30, 2022 2021 Amount Amount % Change (in thousands, except percentages) NeuroStar Advanced Therapy System $ 3,934 $ 2,612 51 % Treatment sessions 11,864 $ 10,259 16 % Other 446 $ 409 9 % Total U.S. revenues $ 16,244 $ 13,280 22 % U.S. NeuroStar Advanced Therapy System revenue for the three months ended September 30, 2022 was $3.9 million, an increase of 51% compared to the three months ended September 30, 2021 revenue of $2.6 million. For the three months ended September 30, 2022 and 2021, the Company sold 49 and 33 systems, respectively, that were recognized as NeuroStar capital revenue during each period. Additionally, for the three months ended September 30, 2022 and 2021, the Company executed 1 and 7 operating lease agreements, respectively, that contributed to operating lease revenue. U.S. Treatment Session revenue for the three months ended September 30, 2022 was $11.9 million, an increase of 16% compared to the three months ended September 30, 2021 revenue of $10.3 million. The revenue growth was primarily driven by an increase in utilization, in particular amount our local per-click customer segment. In the third quarter of 2022, U.S. treatment session revenue per active site increased to $11,364 from $11,163 during the third quarter of 2021. Gross margin for the third quarter of 2022 was 78.4%, an increase of approximately 120 basis points from the third quarter of 2022 gross margin of 77.2%. Operating expenses during the third quarter of 2022 were $20.4 million, an increase of $2.6 million, or 14.6%, compared to $17.8 million in the third quarter of 2021. The increase was primarily driven by our expanded sales force, the opening of NeuroStar University, additional headcount in product development and clinical, as well as increased costs from inflationary pressures. On a sequential basis, compared to the second quarter of 2022, total operating expenses in the third quarter of 2022 were down approximately $1.7 million as a result of cost control measures taken during the period. Net loss for the third quarter of 2022 was $(7.6) million, or $(0.28) per share, as compared to the third quarter 2022 net loss of $(8.2) million, or $(0.31) per share. Net loss per share was based on 26,964,613 and 26,301,361 weighted-average common shares outstanding for the third quarters of 2022 and 2021, respectively. EBITDA for the third quarter of 2022 was $(6.1) million as compared to the third quarter of 2021 EBITDA of $(6.9) million. See the accompanying financial table that reconciles EBITDA, which is a non-GAAP financial measure, to net loss. Cash and cash equivalents were $73.7 million as of September 30, 2022. This compares to cash and cash equivalents of $94.1 million as of December 31, 2021, and $70.9 million as of June 30, 2022. TMS Coverage Policies Updates In October of 2022, multiple Medicare Administrative Contractors (MACs) published and proposed Medicare coverage policies to reduce the number of medication trials required for TMS eligibility, leading to increased access to NeuroStar as a non-drug alternative for treatment resistant mental disorders. The published and proposed updates will affect nearly 8 million covered lives. CGS MAC has published an updated TMS coverage policy, effective December 4, 2022, that reduces the number of prior medication failures for TMS eligibility from four down to two for people suffering from major depressive disorder (MDD). NGS MAC has published a proposed Local Coverage Decision (LCD) considering TMS coverage for obsessive-compulsive disorder (OCD) and is also considering an MDD policy criteria change that would reduce the number of prior medication failures for TMS eligibility from four down to two. 510(k) Clearance for D-Tect MT Accessory The Company has received 510(k) clearance for it’s D-Tect™ MT Accessory, which is the latest innovation in NeuroStar’s commitment to simplify the motor threshold determination for physicians. The FDA-cleared technology aids clinicians by visually reporting the magnitude of finger movements during motor threshold (MT) mapping for treatment of major depressive disorder (MDD). D-Tect also allows the MT determination to be performed by only one person. In addition, practices will be trained on this new product at NeuroStar University, which recently opened in Charlotte, North Carolina. Grand Opening of NeuroStar University (NSU) In September, the Company hosted a ribbon-cutting ceremony to celebrate the grand opening of NeuroStar University in Charlotte, NC. Local government officials, NeuroStar patients and providers, and leaders in the mental health industry were among the 75 attendees. NSU will teach new and existing customers how to enhance patient outcomes, connect with other specialists in their field, and grow their practices using clinical education, enhanced patient awareness and consultation techniques. Business Outlook For the full year 2022, the Company now expects total worldwide revenue to be between $63.0 million and $64.0 million, up from previous guidance of $60.0 million and $62.0 million. For the full year 2022, the Company continues to expect total operating expenses to be between $86.0 million and $88.0 million. For the fourth quarter of 2022, the Company expects to report total worldwide revenue of between $16.0 million and $17.0 million. Webcast and Conference Call Information Neuronetics’ management team will host a conference call on November 8, 2022, beginning at 8:30 a.m. Eastern Time. The conference call will be broadcast live in listen-only mode via webcast at . To listen to the conference call on your telephone, participants may register for the call here. While it is not required, it is recommended you join 10 minutes prior to the event start. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Neuronetics’ website at ir.neuronetics.com. About Neuronetics Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience and the largest transcranial magnetic stimulation (“TMS”) company in the industry, Neuronetics is redefining patient and physician expectations by designing and developing products that improve the quality of life for people suffering from neurohealth conditions. An FDA-cleared, non-drug, noninvasive treatment for people with depression, Neuronetics’ NeuroStar® Advanced Therapy system is the leading TMS treatment for major depressive disorder (“MDD”) in adults with over 4.8 million treatments delivered. NeuroStar is widely researched and backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Our NeuroStar® Advanced Therapy system is also FDA-cleared to treat people suffering from obsessive-compulsive disorder, as well as for the treatment of comorbid anxiety symptoms (“anxious depression”) for adults with MDD suffering from anxiety symptoms. Neuronetics is committed to transforming lives by offering an exceptional treatment option that aims to produce extraordinary results. For safety information and indications for use, visit NeuroStar.com. “Safe harbor” statement under the Private Securities Litigation Reform Act of 1995: Statements in the press release regarding Neuronetics, Inc. (the “Company”) that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “outlook,” “potential,” “believe,” “expect,” “plan,” “anticipate,” “predict,” “may,” “will,” “could,” “would” and “should” as well as the negative of these terms and similar expressions. These statements include those relating to the Company’s business outlook and current expectations for upcoming quarter and fiscal year 2022, including with respect to revenue, operating expense, growth, and any statements of assumptions underlying any of the foregoing items. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to: the impact of COVID 19 on the Company’s operational and budget plans as well as general political and economic conditions, including as a result of efforts by governmental authorities to mitigate COVID 19, such as travel restrictions and third-party business closures and the related impact on resource allocations, manufacturing and supply chains and patient access to commercial products; the Company’s ability to execute its business continuity; the Company’s ability to achieve or sustain profitable operations due to its history of losses; the Company’s reliance on the sale and usage of its NeuroStar Advanced Therapy for Mental Health System to generate revenues; the scale and efficacy of the Company’s salesforce as well as the Company’s ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using the Company’s products; physician and patient demand for treatments using the Company’s products; developments in respect of competing technologies and therapies for the indications that the Company’s products treat; product defects; the Company’s ability to obtain and maintain intellectual property protection for its technology; developments in clinical trials or regulatory review of NeuroStar Advanced Therapy for Mental Health System for additional indications; and developments in regulation in the United States and other applicable jurisdictions. For a discussion of these and other related risks, please refer to the Company’s recent SEC filings which are available on the SEC’s website at These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or changes in the Company’s expectations. Investor Contact: Mike Vallie or Mark Klausner Westwicke Partners 443-213-0499 ir@neuronetics.com Media Contact: EvolveMKD 646-517-4220 NeuroStar@evolvemkd.com NEURONETICS, INC. Statements of Operations (In thousands, except per share data) Three Months ended Nine months ended September 30, September 30, 2022 2021 2022 2021 Revenues $ 16,498 $ 13,799 $ 47,008 $ 40,290 Cost of revenues 3,570 3,144 11,093 8,115 Gross Profit 12,928 10,655 35,915 32,175 Operating expenses: Sales and marketing 11,643 9,827 37,977 27,431 General and administrative 6,391 6,435 19,125 19,220 Research and development 2,348 1,575 6,197 6,179 Total operating expenses 20,382 17,837 63,299 52,830 Loss from Operations (7,454 ) (7,182 ) (27,384 ) (20,655 ) Other (income) expense: Interest expense 1,061 993 3,039 2,955 Other income, net (906 ) (24 ) (1,554 ) (53 ) Net Loss $ (7,609 ) $ (8,151 ) $ (28,869 ) $ (23,557 ) Net loss per share of common stock outstanding, basic and diluted $ (0.28 ) $ (0.31 ) $ (1.08 ) $ (0.94 ) Weighted-average common shares outstanding, basic and diluted 26,965 26,301 26,797 25,179 NEURONETICS, INC. Balance Sheets (In thousands, except per share data) September 30, December 31, 2022 2021 Assets Current assets: Cash and cash equivalents $ 73,698 $ 94,141 Accounts receivable, net 11,963 7,706 Inventory 8,573 6,563 Current portion of net investments in sales-type leases 1,874 2,198 Current portion of prepaid commission expense 1,871 1,559 Current portion of note receivables 80 74 Prepaid expenses and other current assets 3,037 3,090 Total current assets 101,096 115,331 Property and equipment, net 2,109 1,220 Operating lease right-of-use assets 3,459 3,884 Net investments in sales-type leases 1,617 1,697 Prepaid commission expense 7,305 6,763 Long-term note receivable 94 10,110 Other assets 3,555 2,218 Total Assets $ 119,235 $ 141,223 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 2,350 $ 4,299 Accrued expenses 11,493 8,233 Deferred revenue 1,732 2,501 Current portion of operating lease liabilities 818 670 Current portion of long-term debt, net 8,750 — Total current liabilities 25,143 15,703 Long-term debt, net 27,009 35,335 Deferred revenue 981 1,471 Operating lease liabilities 3,111 3,539 Total Liabilities 56,244 56,048 Commitments and contingencies (Note 17) — — Stockholders’ Equity: Preferred stock, $0.01 par value: 10,000 shares authorized; no shares issued or outstanding on September 30, 2022, and December 31, 2021 — — Common stock, $0.01 par value: 200,000 shares authorized; 27,059 and 26,395 shares issued and outstanding on September 30, 2022, and December 31, 2021, respectively 270 264 Additional paid-in capital 400,323 393,644 Accumulated deficit (337,602 ) (308,733 ) Total Stockholders’ Equity 62,991 85,175 Total Liabilities and Stockholders’ Equity $ 119,235 $ 141,223 NEURONETICS, INC. Statements of Cash Flows (In thousands) Nine months ended September 30, 2022 2021 Cash Flows from Operating Activities: Net loss $ (28,869 ) $ (23,557 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 1,044 768 Share-based compensation 6,633 6,166 Non-cash interest expense 513 484 Cost of rental units purchased by customers 92 137 Changes in certain assets and liabilities: Accounts receivable, net (4,257 ) (3,097 ) Inventory (2,299 ) (1,870 ) Net investment in sales-type leases 381 341 Prepaid commission expense (854 ) (602 ) Prepaid expenses and other assets 176 (453 ) Accounts payable (2,199 ) (840 ) Accrued expenses 3,260 (405 ) Deferred revenue (1,260 ) (531 ) Net Cash Used in Operating Activities (27,639 ) (23,459 ) Cash Flows from Investing Activities: Purchases of property and equipment and capitalized software (2,766 ) (1,552 ) Repayment (Issuance) of promissory note 10,000 (7,486 ) Net Cash provided by (Used in) Investing Activities 7,234 (9,038 ) Cash Flows from Financing Activities: Payments of debt issuance costs (90 ) — Proceeds from exercises of stock options 52 2,403 Proceeds from common stock offering — 80,972 Payments of common stock offering issuance costs — (401 ) Net Cash (Used) Provided by Financing Activities (38 ) 82,974 Net (Decrease) Increase in Cash and Cash Equivalents (20,443 ) 50,477 Cash and Cash Equivalents, Beginning of Period 94,141 48,957 Cash and Cash Equivalents, End of Period $ 73,698 $ 99,434 Non-GAAP Financial Measures (Unaudited) EBITDA is not a measure of financial performance under generally accepted accounting principles in the United States, or GAAP, and should not be construed as a substitute for, or superior to, GAAP net loss. However, management uses both the GAAP and non-GAAP financial measures internally to evaluate and manage the Company’s operations and to better understand its business. Further, management believes the addition of the non-GAAP financial measure provides meaningful supplementary information to, and facilitates analysis by, investors in evaluating the Company’s financial performance, results of operations and trends. The Company’s calculation of EBITDA may not be comparable to similarly designated measures reported by other companies, because companies and investors may differ as to what type of events warrant adjustment. The following table reconciles reported net loss to EBITDA: Three Months ended Nine months ended September 30, September 30, 2022 2021 2022 2021 (in thousands) (in thousands) Net loss $ (7,609 ) $ (8,151 ) $ (28,869 ) $ (23,557 ) Interest expense 1,061 993 3,039 2,955 Income taxes — — — — Depreciation and amortization 387 216 1,044 768 EBITDA $ (6,161 ) $ (6,942 ) $ (24,786 ) $ (19,834 )

MALVERN, Pa., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced today that they have received 510(k) clearance for their D-Tect™ MT Accessory, which is the latest innovation in NeuroStar’s commitment to simplify the motor threshold determination for physicians. The FDA-cleared technology aids clinicians by visually reporting the magnitude of finger movements during motor threshold (MT) mapping for treatment of major depressive disorder (MDD). D-Tect also allows the MT determination to be performed by only one person. The D-Tect MT Accessory will initially be available via a limited commercial launch, with a national rollout beginning in mid-September. In addition, practices will be trained on this new product at NeuroStar University, which recently opened in Charlotte, North Carolina. “The FDA clearance for the D-Tect MT Accessory is the next chapter in our plan to simplify and accelerate the MT determination for NeuroStar providers,” stated Cory Anderson, VP of R&D and Clinical. “This product aids physicians as they determine the treatment location and treatment level for new patients, and we’re excited to announce that this patent-pending technology is compatible with all new and existing NeuroStar systems.” The D-Tect MT Accessory is designed to recognize the movement in three areas of the hand, and it does not require cords or sensors to be attached to the patient. This streamlines the process compared to the current visual method and provides the clinician with more data, including a comparison of the response to the current versus previous pulse. The D-Tect MT Accessory complements NeuroStar’s Fast MT™ and the MT Cap innovations, completing the solution for determining the motor threshold, and delivering an average time savings of 40% for physicians during the MT determination. “It’s outstanding to see tangible results from NeuroStar’s ongoing commitment to invest in product innovations that deliver real value to practices like mine by streamlining the entire NeuroStar TMS treatment process,” said David Sikowitz, MD of The TMS Center of New Jersey. “Having the latest technology to assist in determining a patient’s motor threshold will make my team more efficient while also allowing us to deliver the best patient care by personalizing each patient’s treatment while saving time.” The D-Tect MT Accessory is compatible across all NeuroStar systems. For more information on NeuroStar, please visit neurostar.com. About D-Tect™ MT Accessory The D-Tect™ MT Accessory is intended to be used as an accessory of the NeuroStar System to aid in the detection of hand movement and amplitude during motor threshold determination for the treatment of major depressive disorder (MDD). About Neuronetics Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 4.8 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, www.neurostar.com.

MALVERN, Pa., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced today that they have received 510(k) clearance for their D-Tect™ MT Accessory, which is the latest innovation in NeuroStar’s commitment to simplify the motor threshold determination for physicians. The FDA-cleared technology aids clinicians by visually reporting the magnitude of finger movements during motor threshold (MT) mapping for treatment of major depressive disorder (MDD). D-Tect also allows the MT determination to be performed by only one person. The D-Tect MT Accessory will initially be available via a limited commercial launch, with a national rollout beginning in mid-September. In addition, practices will be trained on this new product at NeuroStar University, which recently opened in Charlotte, North Carolina. “The FDA clearance for the D-Tect MT Accessory is the next chapter in our plan to simplify and accelerate the MT determination for NeuroStar providers,” stated Cory Anderson, VP of R&D and Clinical. “This product aids physicians as they determine the treatment location and treatment level for new patients, and we’re excited to announce that this patent-pending technology is compatible with all new and existing NeuroStar systems.” The D-Tect MT Accessory is designed to recognize the movement in three areas of the hand, and it does not require cords or sensors to be attached to the patient. This streamlines the process compared to the current visual method and provides the clinician with more data, including a comparison of the response to the current versus previous pulse. The D-Tect MT Accessory complements NeuroStar’s Fast MT™ and the MT Cap innovations, completing the solution for determining the motor threshold, and delivering an average time savings of 40% for physicians during the MT determination. “It’s outstanding to see tangible results from NeuroStar’s ongoing commitment to invest in product innovations that deliver real value to practices like mine by streamlining the entire NeuroStar TMS treatment process,” said David Sikowitz, MD of The TMS Center of New Jersey. “Having the latest technology to assist in determining a patient’s motor threshold will make my team more efficient while also allowing us to deliver the best patient care by personalizing each patient’s treatment while saving time.” The D-Tect MT Accessory is compatible across all NeuroStar systems. For more information on NeuroStar, please visit neurostar.com. AboutD-Tect™ MT Accessory The D-Tect™ MT Accessory is intended to be used as an accessory of the NeuroStar System to aid in the detection of hand movement and amplitude during motor threshold determination for the treatment of major depressive disorder (MDD). AboutNeuronetics Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 4.8 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, . Media Contact: EvolveMKD 646.517.4220 NeuroStar@evolvemkd.com